BERLIN, Nov 23 (Reuters) - Germany's IDT Biologika plans to start a phase II trial of its experimental COVID-19 vaccine by the end of the year and hopes to be able to apply for approval in 2021, its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback